HIV integrase inhibitors: a new era in the treatment of HIV

被引：57

作者：

Luis Blanco, Jose ^{[1
]}

Whitlock, Gary ^{[2
]}

Milinkovic, Ana ^{[3
]}

Moyle, Graeme ^{[2
]}

机构：

[1] Hosp Clin Barcelona, Barcelona 08037, Spain

[2] Chelsea & Westminster Hosp, London SW10 9NH, England

[3] Univ Collage London, Mortimer Market Ctr, London WC1E 6JB, England

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2015年 / 16卷 / 09期

关键词：

HIV; integrase inhibitors; raltegravir; elvitegravir; dolutegravir; ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE; REVERSE-TRANSCRIPTASE INHIBITOR; BOOSTED PROTEASE INHIBITORS; ANTIRETROVIRAL-NAIVE ADULTS; CO-FORMULATED ELVITEGRAVIR; ONCE-DAILY DOLUTEGRAVIR; DOUBLE-BLIND; INITIAL TREATMENT; INFECTION ANALYSIS; OPEN-LABEL;

D O I：

10.1517/14656566.2015.1044436

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Integrase inhibitors (INN) are the latest class of antiretroviral drugs approved for the treatment of HIV infection and are becoming 'standard' drugs in the treatment of both nave as well as heavily pretreated individuals with HIV. Areas covered: Data on efficacy, safety, tolerability, pharmacokinetics, drug-drug interactions and resistance are reviewed from the pivotal Phase III clinical trials published in PubMed high-impact medical journals or presented at international meetings. Expert opinion: Due to their outstanding data of efficacy, tolerability, safety shared by all three drugs (raltegravir, elvitegravir, dolutegravir) currently belonging to this new family of antiretrovirals - INIs have become part of the recommended initial antiretroviral therapy options. Some differences in dosing, drug-drug interactions and robustness/genetic barrier among the three drugs will provide the physician the characteristics to make the best choice.

引用

页码：1313 / 1324

页数：12

共 48 条

[1] Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial [J].

Arribas, Jose R. ;

Pialoux, Gilles ;

Gathe, Joseph ;

Di Perri, Giovanni ;

Reynes, Jacques ;

Tebas, Pablo ;

Thai Nguyen ;

Ebrahimi, Ramin ;

White, Kirsten ;

Piontkowsky, David .

LANCET INFECTIOUS DISEASES, 2014, 14 (07) :581-589

[2] Dolutegravir: an exciting new kid on the block [J].

Blanco Arevalo, Jose Luis ;

George Whidock, Gary .

EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (04) :573-582

[3] Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir plus emtricitabine/lamivudine plus efavirenz administered on a multiple tablet therapy [J].

Blanco, Jose L. ;

Montaner, Julio S. G. ;

Marconi, Vincent C. ;

Santoro, Maria M. ;

Campos-Loza, Ariel E. ;

Shafer, Robert W. ;

Miller, Michael D. ;

Paredes, Roger ;

Harrigan, Richard ;

Nguyen, Mihn L. ;

Perno, Carlo F. ;

Gonzalez-Hernandez, Lucero A. ;

Gatell, Jose M. .

AIDS, 2014, 28 (17) :2531-2539

[4]

Buzon MJ, 2012, ANTIVIR THER, V17, P355

[5] Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study [J].

Cahn, Pedro ;

Pozniak, Anton L. ;

Mingrone, Horacio ;

Shuldyakov, Andrey ;

Brites, Carlos ;

Andrade-Villanueva, Jaime F. ;

Richmond, Gary ;

Beltran Buendia, Carlos ;

Fourie, Jan ;

Ramgopal, Moti ;

Hagins, Debbie ;

Felizarta, Franco ;

Madruga, Jose ;

Reuter, Tania ;

Newman, Tamara ;

Small, Catherine B. ;

Lombaard, John ;

Grinsztejn, Beatriz ;

Dorey, David ;

Underwood, Mark ;

Griffith, Sandy ;

Min, Sherene .

LANCET, 2013, 382 (9893) :700-708

[6] Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study [J].

Castagna, Antonella ;

Maggiolo, Franco ;

Penco, Giovanni ;

Wright, David ;

Mills, Anthony ;

Grossberg, Robert ;

Molina, Jean-Michel ;

Chas, Julie ;

Durant, Jacques ;

Moreno, Santiago ;

Doroana, Manuela ;

Ait-Khaled, Mounir ;

Huang, Jenny ;

Min, Sherene ;

Song, Ivy ;

Vavro, Cindy ;

Nichols, Garrett ;

Yeo, Jane M. .

JOURNAL OF INFECTIOUS DISEASES, 2014, 210 (03) :354-362

[7] Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study [J].

Clotet, Bonaventura ;

Feinberg, Judith ;

van Lunzen, Jan ;

Khuong-Josses, Marie-Aude ;

Antinori, Andrea ;

Dumitru, Irina ;

Pokrovskiy, Vadim ;

Fehr, Jan ;

Ortiz, Roberto ;

Saag, Michael ;

Harris, Julia ;

Brennan, Clare ;

Fujiwara, Tamio ;

Min, Sherene .

LANCET, 2014, 383 (9936) :2222-2231

[8] Randomized, Double-blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results [J].

Clumeck, Nathan ;

Molina, Jean-Michel ;

Henry, Keith ;

Gathe, Joseph ;

Rockstroh, Juergen K. ;

DeJesus, Edwin ;

Wei, Xuelian ;

White, Kirsten ;

Fordyce, Marshall W. ;

Rhee, Martin S. ;

Szwarcberg, Javier .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 65 (03) :E121-E124

[9] Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection [J].

Cohen, Calvin ;

Elion, Richard ;

Ruane, Peter ;

Shamblaw, David ;

DeJesus, Edwin ;

Rashbaum, Bruce ;

Chuck, Steven L. ;

Yale, Kitty ;

Liu, Hui C. ;

Warren, David R. ;

Ramanathan, Srinivasan ;

Kearney, Brian P. .

AIDS, 2011, 25 (06) :F7-F12

[10] Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy [J].

Curran, Adrian ;

Martinez, Esteban ;

Saumoy, Maria ;

del Rio, Luis ;

Crespo, Manuel ;

Larrousse, Maria ;

Podzamczer, Daniel ;

Burgos, Joaquin ;

Lonca, Montse ;

Domingo, Pere ;

Maria Gatell, Jose ;

Ribera, Esteban .

AIDS, 2012, 26 (04) :475-481

← 1 2 3 4 5 →